BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pellicer M, García-gonzález X, García MI, Robles L, Grávalos C, García-alfonso P, Pachón V, Longo F, Martínez V, Blanco C, Iglesias I, Sanjurjo M, López-fernández LA. Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacological Research 2017;120:133-7. [DOI: 10.1016/j.phrs.2017.03.021] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Qi C, Gao H, Li S, Zong H, Hao H, Zhang L. A Case-Control Study on the Correlation Between Thymidylate Synthase Gene Polymorphisms and Raltitrexed Treatment Combined with Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Treatment. Genet Test Mol Biomarkers 2020;24:156-64. [PMID: 32101052 DOI: 10.1089/gtmb.2019.0111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Wang X, Xie JB, Wu G, Li XL, Han SY. Single nucleotide polymorphisms of ENOSF1 are predictors of therapeutic safety of capecitabine in colorectal cancer. Shijie Huaren Xiaohua Zazhi 2017; 25(35): 3133-3140 [DOI: 10.11569/wcjd.v25.i35.3133] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Helsby NA, Duley J, Burns KE, Bonnet C, Jeong SH, Brenman E, Barlow P, Sharples K, Porter D, Findlay M. A case-control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine-induced gastrointestinal toxicity. Br J Clin Pharmacol 2020;86:155-64. [PMID: 31658382 DOI: 10.1111/bcp.14153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
4 Vitello S, Di Liegro I, Ricciardi MR, Verga C, Amato A, Schiera G, Di Liegro C, Messina G, Proia P. Correlation between polymorphism of TYMS gene and toxicity response to treatment with 5-fluoruracil and capecitabine. Eur J Transl Myol 2020;30:8970. [PMID: 33117504 DOI: 10.4081/ejtm.2020.8970] [Reference Citation Analysis]
5 Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Review of Clinical Pharmacology 2019;12:407-42. [DOI: 10.1080/17512433.2019.1597706] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
6 Hamzic S, Kummer D, Froehlich TK, Joerger M, Aebi S, Palles C, Thomlinson I, Meulendijks D, Schellens JH, García-gonzález X, López-fernández LA, Amstutz U, Largiadèr CR. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. Pharmacological Research 2020;152:104594. [DOI: 10.1016/j.phrs.2019.104594] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
7 Duley JA, Ni M, Shannon C, Norris RL, Sheffield L, Cowley D, Harris M, van Kuilenburg ABP, Helsby N, George R, Charles BG. Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients. Ther Drug Monit 2018;40:495-502. [PMID: 29846282 DOI: 10.1097/FTD.0000000000000532] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 García-gonzález X, López-fernández LA. Using pharmacogenetics to prevent severe adverse reactions to capecitabine. Pharmacogenomics 2017;18:1199-213. [DOI: 10.2217/pgs-2017-0102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
9 Liu D, Li X, Li X, Zhang M, Zhang J, Hou D, Tong Z, Dong M. CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy. Cancer Chemother Pharmacol 2019;83:939-49. [DOI: 10.1007/s00280-019-03809-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cecchin E, De Mattia E, Ecca F, Toffoli G. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. Drug Resist Updat. 2018;39:18-40. [PMID: 30075835 DOI: 10.1016/j.drup.2018.07.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
11 García-González X, Kaczmarczyk B, Abarca-Zabalía J, Thomas F, García-Alfonso P, Robles L, Pachón V, Vaz Á, Salvador-Martín S, Sanjurjo-Sáez M, López-Fernández LA. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine. Cancer Chemother Pharmacol 2020;86:45-54. [PMID: 32529295 DOI: 10.1007/s00280-020-04093-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Marin JJG, Serrano MA, Monte MJ, Sanchez-Martin A, Temprano AG, Briz O, Romero MR. Role of Genetic Variations in the Hepatic Handling of Drugs. Int J Mol Sci 2020;21:E2884. [PMID: 32326111 DOI: 10.3390/ijms21082884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Palles C, Fotheringham S, Chegwidden L, Lucas M, Kerr R, Mozolowski G, Rosmarin D, Taylor JC, Tomlinson I, Kerr D. An Evaluation of the Diagnostic Accuracy of a Panel of Variants in DPYD and a Single Variant in ENOSF1 for Predicting Common Capecitabine Related Toxicities. Cancers (Basel) 2021;13:1497. [PMID: 33805100 DOI: 10.3390/cancers13071497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zanger UM, Klein K, Kugler N, Petrikat T, Ryu CS. Epigenetics and MicroRNAs in Pharmacogenetics. Pharmacogenetics. Elsevier; 2018. pp. 33-64. [DOI: 10.1016/bs.apha.2018.02.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Lozano E, Briz O, Macias RIR, Serrano MA, Marin JJG, Herraez E. Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition. J Pers Med. 2018;8. [PMID: 29659532 DOI: 10.3390/jpm8020014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
16 Mosedale M, Cai Y, Eaddy JS, Corty RW, Nautiyal M, Watkins PB, Valdar W. Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach. Toxicol Sci 2019;172:265-78. [PMID: 31501888 DOI: 10.1093/toxsci/kfz199] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
17 Varughese LA, Lau-Min KS, Cambareri C, Damjanov N, Massa R, Reddy N, Oyer R, Teitelbaum U, Tuteja S. DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation. Pharmacotherapy 2020;40:1108-29. [PMID: 32985005 DOI: 10.1002/phar.2463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Salvador-Martín S, García-González X, García MI, Blanco C, García-Alfonso P, Robles L, Grávalos C, Pachón V, Longo F, Martínez V, Sanjurjo-Sáez M, López-Fernández LA. Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan. Pharmacol Res 2018;136:133-9. [PMID: 30213564 DOI: 10.1016/j.phrs.2018.08.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
19 Chen F, Zhang B, Parker RB, Laizure SC. Clinical implications of genetic variation in carboxylesterase drug metabolism. Expert Opinion on Drug Metabolism & Toxicology 2018;14:131-42. [DOI: 10.1080/17425255.2018.1420164] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
20 Dong SQ, Wang TM, Zhang JB, He YQ, Xue WQ, Wu ZY, Yang DW, Cao LJ, Huang JW, Li XZ, Zhang PF, Zheng XH, Jia WH. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer. Cancer Res Treat 2021;53:724-32. [PMID: 33285053 DOI: 10.4143/crt.2020.457] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Schaller L, Lauschke VM. The genetic landscape of the human solute carrier (SLC) transporter superfamily. Hum Genet 2019;138:1359-77. [PMID: 31679053 DOI: 10.1007/s00439-019-02081-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]